Ignite Creation Date:
2024-05-06 @ 9:44 AM
Last Modification Date:
2024-10-26 @ 12:18 PM
Study NCT ID:
NCT03055221
Status:
COMPLETED
Last Update Posted:
2024-01-05
First Post:
2017-02-09
Brief Title:
TRUST-2 Safety and Efficacy of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension PAH
Sponsor:
United Therapeutics
Organization:
United Therapeutics
Study Overview
Official Title:
TRUST-2 An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension PAH
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TRUST-2
Brief Summary:
This was an open-label extension of Study RIV-PH-402 TRUST-1 Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension PAH Trial Subjects who completed Study RIV-PH-402 were eligible to enroll
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None